Cambridge Cognition Holdings (GB:COG) has released an update.
Cambridge Cognition’s spin-out company, Monument Therapeutics, has secured a £1.0 million investment to advance its novel schizophrenia treatment, MT1988. This funding is expected to enhance Monument’s clinical development efforts, potentially complementing existing schizophrenia medications. Cambridge Cognition holds a 22.1% stake in Monument, anticipating a significant increase in its shareholding valuation.
For further insights into GB:COG stock, check out TipRanks’ Stock Analysis page.
